SK284608B6 - Kompozície obsahujúce 5-hydroxyindol ako modulátor nikotínového receptora a ich použitie - Google Patents

Kompozície obsahujúce 5-hydroxyindol ako modulátor nikotínového receptora a ich použitie Download PDF

Info

Publication number
SK284608B6
SK284608B6 SK1570-2000A SK15702000A SK284608B6 SK 284608 B6 SK284608 B6 SK 284608B6 SK 15702000 A SK15702000 A SK 15702000A SK 284608 B6 SK284608 B6 SK 284608B6
Authority
SK
Slovakia
Prior art keywords
nicotinic receptor
agonist
receptor agonist
modulator
nicotinic
Prior art date
Application number
SK1570-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK15702000A3 (sk
Inventor
David Gurley
Thomas Lanthorn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK15702000A3 publication Critical patent/SK15702000A3/sk
Publication of SK284608B6 publication Critical patent/SK284608B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Addiction (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SK1570-2000A 1998-05-04 1999-04-28 Kompozície obsahujúce 5-hydroxyindol ako modulátor nikotínového receptora a ich použitie SK284608B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/071,826 US6277870B1 (en) 1998-05-04 1998-05-04 Use
PCT/SE1999/000700 WO1999056745A1 (en) 1998-05-04 1999-04-28 New use

Publications (2)

Publication Number Publication Date
SK15702000A3 SK15702000A3 (sk) 2001-08-06
SK284608B6 true SK284608B6 (sk) 2005-07-01

Family

ID=22103848

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1570-2000A SK284608B6 (sk) 1998-05-04 1999-04-28 Kompozície obsahujúce 5-hydroxyindol ako modulátor nikotínového receptora a ich použitie

Country Status (27)

Country Link
US (2) US6277870B1 (hu)
EP (1) EP1079828B1 (hu)
JP (1) JP2002513757A (hu)
KR (1) KR20010043266A (hu)
CN (2) CN1637149A (hu)
AR (1) AR016217A1 (hu)
AT (1) ATE249827T1 (hu)
AU (1) AU770849B2 (hu)
BR (1) BR9910180A (hu)
CA (1) CA2331070A1 (hu)
DE (1) DE69911400T2 (hu)
EE (1) EE200000640A (hu)
HK (1) HK1034205A1 (hu)
HU (1) HUP0102504A3 (hu)
ID (1) ID27289A (hu)
IL (1) IL139145A0 (hu)
IS (1) IS5699A (hu)
MY (1) MY116027A (hu)
NO (1) NO20005503L (hu)
PL (1) PL343923A1 (hu)
RU (1) RU2225203C2 (hu)
SK (1) SK284608B6 (hu)
TR (1) TR200003244T2 (hu)
TW (1) TW542718B (hu)
UA (1) UA65617C2 (hu)
WO (1) WO1999056745A1 (hu)
ZA (1) ZA200006133B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
NZ533259A (en) * 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2487236A1 (en) 2002-05-09 2003-11-20 Memory Pharmaceuticals Corporation Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
CA2495248A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP2058275A1 (en) 2003-01-07 2009-05-13 Ramot at Tel-Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
WO2005027901A1 (en) 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
RS20060391A (en) 2003-12-22 2008-11-28 Memory Pharmaceuticals Corporation, Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2- benzisothiazoles, and preparation and uses thereof
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
RU2386633C2 (ru) 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
US8568637B2 (en) * 2004-08-02 2013-10-29 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures
EP1793816B1 (en) * 2004-08-19 2012-01-04 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
CA2591817A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US7375219B2 (en) * 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
TW200808780A (en) * 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
BRPI0820632A2 (pt) * 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
WO2009064505A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
MY159826A (en) 2008-11-19 2017-02-15 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
NZ707955A (en) 2010-09-23 2016-03-31 Abbvie Bahamas Ltd Monohydrate of an azaadamantane derivative
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649009B1 (fr) * 1989-07-03 1991-10-11 Oreal Procede de teinture des fibres keratiniques a base de monohydroxyindole et de 5,6-dihydroxyindole et composition mise en oeuvre
US5272155A (en) * 1991-12-05 1993-12-21 Abbott Laboratories (+)-2-methylpiperidine as modulator of cholinergic systems
HUT74949A (en) * 1993-09-10 1997-03-28 Cytomed Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
BR9508751A (pt) * 1994-08-24 1997-08-12 Astra Ab Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do composto
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use

Also Published As

Publication number Publication date
BR9910180A (pt) 2001-01-09
CA2331070A1 (en) 1999-11-11
DE69911400T2 (de) 2004-07-08
ATE249827T1 (de) 2003-10-15
NO20005503D0 (no) 2000-11-01
ZA200006133B (en) 2002-01-30
TW542718B (en) 2003-07-21
PL343923A1 (en) 2001-09-10
US6277870B1 (en) 2001-08-21
US20010041732A1 (en) 2001-11-15
RU2225203C2 (ru) 2004-03-10
IL139145A0 (en) 2001-11-25
AR016217A1 (es) 2001-06-20
AU770849B2 (en) 2004-03-04
HK1034205A1 (en) 2001-10-19
EP1079828B1 (en) 2003-09-17
WO1999056745A1 (en) 1999-11-11
MY116027A (en) 2003-10-31
NO20005503L (no) 2001-01-04
KR20010043266A (ko) 2001-05-25
SK15702000A3 (sk) 2001-08-06
TR200003244T2 (tr) 2001-03-21
DE69911400D1 (de) 2003-10-23
IS5699A (is) 2000-11-01
HUP0102504A2 (hu) 2001-11-28
JP2002513757A (ja) 2002-05-14
EE200000640A (et) 2002-04-15
HUP0102504A3 (en) 2002-12-28
UA65617C2 (uk) 2004-04-15
AU4302399A (en) 1999-11-23
ID27289A (id) 2001-03-22
EP1079828A1 (en) 2001-03-07
US6861443B2 (en) 2005-03-01
CN1637149A (zh) 2005-07-13
CN1299279A (zh) 2001-06-13

Similar Documents

Publication Publication Date Title
SK284608B6 (sk) Kompozície obsahujúce 5-hydroxyindol ako modulátor nikotínového receptora a ich použitie
Kilpatrick et al. CNS 7056: a novel ultra–short-acting benzodiazepine
Rousseaux et al. Sigma receptors [σ Rs]: biology in normal and diseased states
Paillé et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition
Boehm et al. Somatostatin inhibits excitatory transmission at rat hippocampal synapses via presynaptic receptors
Bale et al. Inhibition of neuronal nicotinic acetylcholine receptors by the abused solvent, toluene
Copani et al. Nootropic drugs positively modulate α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid‐sensitive glutamate receptors in neuronal cultures
Chen et al. Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats
Castro et al. Direct inhibition of the N‐methyl‐D‐aspartate receptor channel by dopamine and (+)‐SKF38393
Aira et al. Time-dependent cross talk between spinal serotonin 5-HT2A receptor and mGluR1 subserves spinal hyperexcitability and neuropathic pain after nerve injury
Pittaluga et al. Somatostatin-induced activation and up-regulation of N-methyl-D-aspartate receptor function: mediation through calmodulin-dependent protein kinase II, phospholipase C, protein kinase C, and tyrosine kinase in hippocampal noradrenergic nerve endings
Sershen et al. Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats
Nagy et al. Converging Evidence on D-Amino Acid Oxidase–Dependent Enhancement of Hippocampal Firing Activity and Passive Avoidance Learning in Rats
Gerra et al. Neuroendocrine correlates of antisocial personality disorder in abstinent heroin‐dependent subjects
Kirby et al. Developmental Changes in Serotonin and 5-HydroxyindoIeacetic Acid Concentrations and Opiate Receptor Binding in Rat Spinal Cord Following Neonatal 5, 7-Dihydroxytryptamine Treatment
Zhang et al. TREM2 deficiency impairs the energy metabolism of Schwann cells and exacerbates peripheral neurological deficits
US6756398B1 (en) Positive modulators of nicotinic receptor agonists
NZ507623A (en) Positive modulator of a nicotinic acetylcholine receptor
CZ20004079A3 (cs) Nové použití
MXPA00010690A (en) New use
Badanavalu et al. Nicotine is neuroprotective to neonatal neurons of sympathetic ganglion in rat
Wu Modulation of ligand-gated receptors in the central nervous system
KAWASAKI et al. NEUROPROTECTIVE ACTIONS OF CALCIUM CHANNEL BLOCKERS IN HIPPOCAMPAL SLICE PREPARATIONS OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RAT
Moga Heterogeneity and dynamic regulation of glutamate receptors underlying plasticity in the hippocampus
O'Leary Nicotinic acetylcholine receptor regulation of the noradrenergic system in the developing rat brain